SETD2 and nonpapillary renal cell carcinoma: Hence, SETD2 loss-of-function mutations were identified in 10 %∼20 % of primary ccRCC tumors, increasing to 30 %∼60 % of metastatic ccRCC tumors, H3K36me3 being reduced in distant metastases [74].